0
500
1,000
1,500
2,000
2,500
3,000
3,500
JAN
FEB
MAR AP
R
MAY JUN
JUL
AUG
SEP
OCT
NO
V
DEC
Num
ber o
f new
CL c
ases
ACL 2015 ACL 2014ZCL 2015 ZCL 2014
VL ACL ZCL MCL
Endemicity status: Endemic Endemic Endemic Non endemic
Number of new cases (incidence): 8 27,787 1,605 N/A
Number of relapses1: No data 375 No data N/A
Total number of cases 8 28,162 1,605 N/AImported cases (#, %): No data No data No data No data
Gender distribution (% F): 38 50 48 N/A
Age group distribution (%, < 5/5-14/>14): (88/12/0) (23/40/37) (42/27/31) N/A
Incidence rate (cases/10,000 population in endemic areas): 0.06 27.23 13.78 N/ANumber of endemic 2nd sub-national administrative level divisions: No data 254 16 N/A
Population at risk2 (%, # at risk/total population): 5% 1,606,414/32,527,000 32 % 10,340,735/
32,527,000 4 % 1,164,373/32,527,000 N/A
Was there any outbreak? No data No data No data N/A
Number of new3 foci: No data No data No data N/A
COUNTRY GENERAL INFORMATION (WHO, 2015)
Total population: 32,527,000Gender F /M (%): 49.3 / 50.7Population, age group <15/ ≥15 years (%): 47 / 53Life expectancy at birth (F/M, years) (2015): 62 / 59GDP (PPP int $): 2,000Income status: LowNumber of 2nd sub-national administrative level divisions, name: 399, District
Leishmaniasis country profile — 2015(Published Dec. 2017)
Afghanistan
EPIDEMIOLOGY
N/A = Not applicable; 1 Relapse in this country is defined as: no definition available; 2 Defined as “Number of people living in 2nd sub-national administrative level endemic areas”; 3 Defined as “In this reporting period, an area at the 2nd sub-national administrative level reporting cases for the first time ever”
Monthly distribution of new cases (January-December)
Cutaneous leishmaniasisVisceral leishmaniasis
Incidence rate/10,000 (at the national level) and number of new cases from 1998 to 2015
2015 JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DECVL 1 2 1 1 1 1 1 0 0 0 1 0ACL 2,407 3,065 2,684 2,934 2,444 2,245 1,391 2,275 1,756 1,938 2,209 2,814ZCL 116 46 50 35 27 27 18 34 41 362 535 314VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL= zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis
0
1
2
3
4
5
JAN
FEB
MAR AP
R
MAY JUN
JUL
AUG
SEP
OCT
NO
V
DEC
Num
ber o
f new
VL
case
s VL 2015 VL 2014
Num
ber o
f new
VL
case
s
Num
ber o
f new
CL
case
s
0.000
0.001
0.002
0.003
0.004
0.005
0.006
0.007
0.008
0.009
0
5
10
15
20
25
30
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
Inci
denc
e ra
te (/
10 0
00)
Num
ber o
f pr
imar
y VL
cas
es
VL cases
VL incidence rate
Visceral leishmaniasis
Num
ber o
f new
VL
case
s
Inci
denc
e ra
te (/
10,0
00)
* * * * * * * * * ** * 0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
Incid
ence
rate
(/10
000
)
ZCL cases
ACL cases
ACL incidence rate
ZCL incidence rate
Inci
denc
e ra
te (/
10,0
00)
Cutaneous leishmaniasis
* * * * *Num
ber o
f new
CL
case
s
* No data
* No data
Disease distribution of new VL and CL cases at district level per 10,000 population (2015)Visceral leishmaniasis Cutaneous leishmaniasis
Year Leishmaniasis National Control Programme (LNCP) was established: 2007Type of surveillance: VerticalIs there a vector control programme? NoType of insecticide used for Indoor residual Spraying (IRS): Not availableYear latest national guidelines: 2014Is leishmaniasis notifiable (mandatory report)? NoIs there a reservoir host control programme? No
Number of leishmaniasis health facilities: 23
CONTROL AND SURVEILLANCE
DIAGNOSIS VL ACL ZCL MCL
Number of people screened actively for: No data No data No data N/ANumber of people screened passively for: 8 28,162 No data N/ACases diagnosed by RDT* (%, # RDT+/ total VL cases): No data N/A N/A N/AProportion of positive RDT* (%, # RDT+/total RDT): No data N/A N/A N/ACases diagnosed by direct exam* (parasitology) (%, # slides + / total cases): 100%, (8/8) No data No data N/AProportion of positive slides* (%, # slides + / total slides): 100%, (8/8) No data No data N/A
Cases diagnosed clinically* (%, # clinical cases/ total cases): 0%, (0/8) No data 100% (1,605/1,605) N/A
Proportion of CL cases with lesions equal to or greater than 4cm*: N/A No data No data N/AProportion of CL cases with 4 or more lesions*: N/A no data No data N/APercentage of cases with HIV coinfection*: 0%, (0/8) N/A N/A N/A
TREATMENT AND MEDICINESIs treatment provided for free in the public sector? YesAntileishmanial medicines included in the National Medicine List: Not available
TREATMENT OUTCOME VL ACL ZCLProportion of cases treated*(%, # treated cases/ total cases): 100% (8/8) 100 % (27,787/27,787) 100% (1,605/1,605)Initial cure rate*(%, # cases initially cured /total cases): 88% (7/8) No data No dataFailure rate4*(%, # patients with treatment failure /total cases): 0% (0/8) No data No dataCase fatality rate*(%, # patients who died/ total cases): 0% (0/8) No data No data
VL = visceral leishmaniasis; ACL = anthroponotic cutaneous leishmaniasis; ZCL= zoonotic cutaneous leishmaniasis; MCL = mucocutaneous leishmaniasis4 Failure in this country is defined as: no definition available * These indicators only apply to new cases
ACL
ZCL
The boundaries and names shown and the designations used on these maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.Map production: WHO/HTM/NTD/IDM
N/A = Not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus
Data source: Ministry of Health, Afghanistan© WHO, 2017. All rights reserved
www.who.int/leishmaniasis/Map-VL-Afghanistan-2015.png
www.who.int/leishmaniasis/Map-ACL-
Afghanistan-2015.png
www.who.int/leishmaniasis/Map-ZCL-
Afghanistan-2015.png